Quick Dispatch:
Your glp-1/glucagon dual receptor agonist Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1/glucagon dual receptor agonist Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies ships.
Need Help?
Questions about glp-1/glucagon dual receptor agonist Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1/glucagon dual receptor agonist Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies in your area.
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
28.10
Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight
22.23
Understanding GLP-1 receptor agonists and their impact on drug discovery
21.64
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal
27.95
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
20.39
Frontiers
29.70
From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer
26.61
